EVMN
Evommune, Inc.
Price Chart
Latest Quote
$21.92
+0.56 (+2.62%)
Current Price
| Previous Close | $21.36 |
| Open | $21.50 |
| Day High | $23.12 |
| Day Low | $21.35 |
| Volume | 152,526 |
Stock Information
| Shares Outstanding | 36.02M |
| Total Debt | $9.11M |
| Cash Equivalents | $211.46M |
| Revenue | $10.00M |
| Net Income | $-75.99M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $789.52M |
| EPS (TTM) | $-2.11 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $567.00M |
| Sales | $10.00M |
| Income | $-75.99M |
| Book/sh | $8.46 |
| Cash/sh | $5.87 |
| Employees | 48 |
Financial Ratios
| Quick Ratio | 19.94 |
| Current Ratio | 20.36 |
| Debt/Eq | 2.99 |
Returns & Margins
| ROA | -29.72% |
| ROE | -44.95% |
| Gross Margin | 100.00% |
| Operating Margin | -899.93% |
Ownership
| Insider Ownership | 7.91% |
| Institutional Ownership | 110.85% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -6.83 |
| P/S | 78.95 |
| P/B | 2.59 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $52.25 |
Technical Indicators
| SMA20 | $21.25 |
| SMA50 | $23.26 |
| RSI | 48.68 |
| ATR | 1.4185 |
| Shares Float | 19.98M |
| Short Float | 16.40% |
| Short Ratio | 9.37 |
| Rel Volume | 0.35 |
Performance History
| Week | +10.54% |
| Month | -1.62% |
| Quarter | -6.04% |
| 6 Months | +37.69% |
| YTD | +26.63% |
| 10 Years | +8.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-22 | $21.92 | 152,526 |
| 2026-06-18 | $21.36 | 665,000 |
| 2026-06-17 | $20.65 | 602,900 |
| 2026-06-16 | $20.05 | 344,600 |
| 2026-06-15 | $20.84 | 447,800 |
| 2026-06-12 | $19.83 | 462,700 |
| 2026-06-11 | $20.69 | 810,600 |
| 2026-06-10 | $20.49 | 562,900 |
| 2026-06-09 | $20.49 | 378,900 |
| 2026-06-08 | $20.19 | 335,700 |
| 2026-06-05 | $19.92 | 417,300 |
| 2026-06-04 | $20.69 | 440,300 |
| 2026-06-03 | $19.73 | 272,000 |
| 2026-06-02 | $19.82 | 387,900 |
| 2026-06-01 | $22.17 | 451,400 |
| 2026-05-29 | $23.23 | 493,300 |
| 2026-05-28 | $23.33 | 413,100 |
| 2026-05-27 | $23.34 | 346,500 |
| 2026-05-26 | $23.35 | 391,900 |
| 2026-05-22 | $22.87 | 376,700 |
About Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products include EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
đ° Latest News
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles
Motley Fool âĸ 2026-06-08T11:16:03Z
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
Motley Fool âĸ 2026-05-31T14:39:50Z
Companies Like Evommune (NYSE:EVMN) Are In A Position To Invest In Growth
Simply Wall St. âĸ 2026-05-11T12:05:24Z
Evommune's Chronic-Hives Drug May See Wider Use If Trial Succeeds, RBC Says
MT Newswires âĸ 2026-04-10T15:45:24ZBiotechâs IPO comeback; Trumpâs tariff loophole for pharma
Pharma Voice âĸ 2026-04-10T08:00:00Z
Evommune bucked biotech IPO drought and is focused on the long game
Pharma Voice âĸ 2026-04-07T08:00:00Z
Apogee strengthens case for longer-lasting eczema drug
BioPharma Dive âĸ 2026-03-23T12:15:00Z
Evommune Stock Sees RS Rating Rise To 91
Investor's Business Daily âĸ 2026-03-18T17:11:04Z
Block upgraded, Starbucks downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-03-18T13:34:42Z
1 UnderâtheâRadar Biotech to Buy for Potential 10X Growth in the Next Decade
Motley Fool âĸ 2026-03-10T14:11:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $13,000,000 | - |
| Operating Revenue | $13,000,000 | - |
| Expenses | ||
| Total Expenses | $94,071,000 | - |
| Other Income Expense | $8,878,000 | - |
| Other Non Operating Income Expenses | $-50,000 | - |
| Net Non Operating Interest Income Expense | $3,323,000 | - |
| Operating Expense | $94,071,000 | - |
| General And Administrative Expense | $20,029,000 | - |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-68,870,000 | - |
| Net Interest Income | $3,323,000 | - |
| Interest Income | $3,323,000 | - |
| Normalized Income | $-77,798,000 | - |
| Net Income From Continuing And Discontinued Operation | $-68,870,000 | - |
| Total Operating Income As Reported | $-81,071,000 | - |
| Net Income Common Stockholders | $-68,870,000 | - |
| Net Income | $-68,870,000 | - |
| Net Income Including Noncontrolling Interests | $-68,870,000 | - |
| Net Income Continuous Operations | $-68,870,000 | - |
| Pretax Income | $-68,870,000 | - |
| Interest Income Non Operating | $3,323,000 | - |
| Operating Income | $-81,071,000 | - |
| Per Share | ||
| Diluted EPS | $-11.22 | $-4.27 |
| Basic EPS | $-11.22 | $-4.27 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | - |
| Tax Rate For Calcs | $0 | - |
| Normalized EBITDA (Bullshit earnings) | $-88,610,000 | - |
| Total Unusual Items | $8,928,000 | - |
| Total Unusual Items Excluding Goodwill | $8,928,000 | - |
| Reconciled Depreciation | $1,389,000 | - |
| EBITDA (Bullshit earnings) | $-79,682,000 | - |
| EBIT | $-81,071,000 | - |
| Diluted Average Shares | $6,136,636 | $16,000,096 |
| Basic Average Shares | $6,136,636 | $16,000,096 |
| Diluted NI Availto Com Stockholders | $-68,870,000 | - |
| Otherunder Preferred Stock Dividend | $0 | - |
| Gain On Sale Of Security | $8,928,000 | - |
| Research And Development | $74,042,000 | - |
| Selling General And Administration | $20,029,000 | - |
| Other Gand A | $7,484,000 | - |
| Salaries And Wages | $12,545,000 | - |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $205,566,000 | - |
| Total Assets | $224,946,000 | - |
| Total Non Current Assets | $71,468,000 | - |
| Other Non Current Assets | $1,516,000 | - |
| Investmentin Financial Assets | $67,489,000 | $0 |
| Current Assets | $153,478,000 | - |
| Other Current Assets | $4,278,000 | - |
| Cash Cash Equivalents And Short Term Investments | $149,200,000 | - |
| Cash And Cash Equivalents | $44,063,000 | - |
| Debt | ||
| Total Debt | $1,713,000 | $1,022,000 |
| Long Term Debt And Capital Lease Obligation | $1,471,000 | $535,000 |
| Current Debt And Capital Lease Obligation | $242,000 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $19,380,000 | - |
| Total Non Current Liabilities Net Minority Interest | $1,471,000 | - |
| Current Liabilities | $17,909,000 | - |
| Other Current Liabilities | $364,000 | - |
| Current Deferred Liabilities | $0 | - |
| Payables And Accrued Expenses | $12,369,000 | - |
| Payables | $7,756,000 | - |
| Accounts Payable | $7,756,000 | - |
| Equity | ||
| Common Stock Equity | $205,566,000 | - |
| Total Equity Gross Minority Interest | $205,566,000 | - |
| Stockholders Equity | $205,566,000 | - |
| Retained Earnings | $-221,089,000 | - |
| Preferred Securities Outside Stock Equity | $0 | - |
| Other | ||
| Ordinary Shares Number | $31,524,093 | - |
| Share Issued | $31,524,093 | - |
| Tangible Book Value | $205,566,000 | - |
| Invested Capital | $205,566,000 | - |
| Working Capital | $135,569,000 | - |
| Capital Lease Obligations | $1,713,000 | $1,022,000 |
| Total Capitalization | $205,566,000 | - |
| Additional Paid In Capital | $426,652,000 | - |
| Capital Stock | $3,000 | - |
| Common Stock | $3,000 | - |
| Long Term Capital Lease Obligation | $1,471,000 | $535,000 |
| Current Deferred Revenue | $0 | - |
| Current Capital Lease Obligation | $242,000 | - |
| Pensionand Other Post Retirement Benefit Plans Current | $4,934,000 | - |
| Current Accrued Expenses | $4,613,000 | - |
| Investments And Advances | $67,489,000 | $0 |
| Held To Maturity Securities | $67,489,000 | $0 |
| Net PPE | $2,463,000 | - |
| Accumulated Depreciation | $-1,559,000 | $-948,000 |
| Gross PPE | $4,022,000 | $2,746,000 |
| Leases | $528,000 | $458,000 |
| Construction In Progress | $35,000 | $0 |
| Other Properties | $1,469,000 | $472,000 |
| Machinery Furniture Equipment | $1,990,000 | $1,816,000 |
| Properties | $0 | $0 |
| Other Short Term Investments | $105,137,000 | - |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 |
|---|---|
| Free Cash Flow | |
| Free Cash Flow | $-76,676,000 |
| Operating Activities | |
| Operating Cash Flow | $-76,441,000 |
| Cash Flow From Continuing Operating Activities | $-76,441,000 |
| Operating Gains Losses | $-8,928,000 |
| Investing Activities | |
| Capital Expenditure | $-235,000 |
| Investing Cash Flow | $-115,307,000 |
| Cash Flow From Continuing Investing Activities | $-115,307,000 |
| Financing Activities | |
| Issuance Of Capital Stock | $65,228,000 |
| Financing Cash Flow | $220,763,000 |
| Cash Flow From Continuing Financing Activities | $220,763,000 |
| Net Other Financing Charges | $-1,382,000 |
| Net Preferred Stock Issuance | $65,228,000 |
| Preferred Stock Issuance | $65,228,000 |
| Other | |
| Repayment Of Debt | $-373,000 |
| Interest Paid Supplemental Data | $7,000 |
| End Cash Position | $45,478,000 |
| Beginning Cash Position | $16,463,000 |
| Changes In Cash | $29,015,000 |
| Proceeds From Stock Option Exercised | $157,290,000 |
| Net Issuance Payments Of Debt | $-373,000 |
| Net Long Term Debt Issuance | $-373,000 |
| Long Term Debt Payments | $-373,000 |
| Net Investment Purchase And Sale | $-115,072,000 |
| Sale Of Investment | $84,100,000 |
| Purchase Of Investment | $-199,172,000 |
| Net PPE Purchase And Sale | $-235,000 |
| Purchase Of PPE | $-235,000 |
| Change In Working Capital | $-4,119,000 |
| Change In Other Working Capital | $-3,000,000 |
| Change In Other Current Liabilities | $-730,000 |
| Change In Payables And Accrued Expense | $1,981,000 |
| Change In Accrued Expense | $2,818,000 |
| Change In Payable | $-837,000 |
| Change In Account Payable | $-837,000 |
| Change In Prepaid Assets | $-2,370,000 |
| Other Non Cash Items | $-1,769,000 |
| Stock Based Compensation | $5,856,000 |
| Depreciation Amortization Depletion | $1,389,000 |
| Depreciation And Amortization | $1,389,000 |
| Gain Loss On Investment Securities | $-8,928,000 |
| Net Income From Continuing Operations | $-68,870,000 |
Fetched: 2026-06-14